Shares of Orthofix International NV (NASDAQ:OFIX) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus target price of $50.00 for the company and are predicting that the company will post $0.34 EPS for the current quarter, according to Zacks. Zacks has also given Orthofix International NV an industry rank of 108 out of 265 based on the ratings given to related companies.

A number of brokerages have commented on OFIX. Zacks Investment Research cut shares of Orthofix International NV from a “buy” rating to a “hold” rating in a research report on Tuesday, July 5th. TheStreet cut shares of Orthofix International NV from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd.

In other news, insider Michael Finegan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $45.16, for a total value of $1,129,000.00. Following the transaction, the insider now owns 51,670 shares in the company, valued at $2,333,417.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.10% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Orthofix International NV by 7.6% in the second quarter. Vanguard Group Inc. now owns 1,445,396 shares of the medical device company’s stock valued at $61,285,000 after buying an additional 101,509 shares in the last quarter. Numeric Investors LLC boosted its position in shares of Orthofix International NV by 15.7% in the second quarter. Numeric Investors LLC now owns 670,203 shares of the medical device company’s stock valued at $28,417,000 after buying an additional 91,144 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Orthofix International NV by 25.1% in the second quarter. Acadian Asset Management LLC now owns 660,196 shares of the medical device company’s stock valued at $27,993,000 after buying an additional 132,537 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Orthofix International NV by 78.7% in the first quarter. Renaissance Technologies LLC now owns 456,379 shares of the medical device company’s stock valued at $18,949,000 after buying an additional 201,020 shares in the last quarter. Finally, Gabelli Funds LLC boosted its position in shares of Orthofix International NV by 0.3% in the second quarter. Gabelli Funds LLC now owns 290,450 shares of the medical device company’s stock valued at $12,315,000 after buying an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 91.26% of the company’s stock.

Shares of Orthofix International NV (NASDAQ:OFIX) traded down 1.27% during mid-day trading on Wednesday, reaching $43.61. 20,783 shares of the company’s stock traded hands. Orthofix International NV has a 12-month low of $32.25 and a 12-month high of $48.25. The company’s market cap is $790.39 million. The firm has a 50-day moving average of $43.80 and a 200 day moving average of $43.71.

Orthofix International NV (NASDAQ:OFIX) last issued its quarterly earnings results on Monday, August 1st. The medical device company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.08. Orthofix International NV had a negative net margin of 0.37% and a positive return on equity of 8.50%. The business had revenue of $104.10 million for the quarter, compared to analysts’ expectations of $102.40 million. During the same period last year, the business earned $0.36 earnings per share. The business’s quarterly revenue was up 3.1% on a year-over-year basis. Equities analysts forecast that Orthofix International NV will post $1.41 EPS for the current year.

About Orthofix International NV

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

5 Day Chart for NASDAQ:OFIX

Get a free copy of the Zacks research report on Orthofix International NV (OFIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orthofix International NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International NV and related companies with Analyst Ratings Network's FREE daily email newsletter.